Skip to content
lifestyle.cosmeticsurgeryinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tango Therapeutics Sub, Inc
Tango Therapeutics Announces Executive Chair Transition
August 6, 2026
Tango Therapeutics Appoints Robert Azelby to Board of Directors
June 22, 2026
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
June 9, 2026
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 13, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
April 15, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2026
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
March 5, 2026
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
February 18, 2026